Aurigene Discovery Technologies Limited

Aurigene Oncology Limited

Curis, Inc.

Orion Corporation

Auirgene Discovery Technologies Limited

Muralidhara Ramachandra

Pottayil Govindan Nair Sasikumar

Seetharamaiah Setty Sudarshan Naremaddepalli

Pottayil Govindan N Sasikumar

Chennakrishnareddy Gundala

Leena Khare Satyam

Girish Chandrappa Daginakatte

Timothy L Wyant

Nagaraj Gowda

Kiran Aithal Balkudru

Suresh Kumar Vadlamani

Raghuveer K Ramachandra

Adam S Lazorchak

Krishnaprasad Subbarao

K Rajeev Shrimali

Susanta Samajdar

Sanjita Sasmal

Dinesh Chikkanna

Seetharamaiah Setty S Naremaddepalli

Vinayak Vasantrao Khairnar

Sreenivas Kandepu

Pottayil G N Sasikumar

Rajeev Goswami

Anil Kumar Vuppala

Ramesh Veludandi

Ramesh Sistla

Chakshusmathi Ghadiyaram

Koteswara Rao Vemula

Pottayil Govindan Sasikumar

Seetharamaiah Setty Naremaddepalli

The present invention relates to a composition of a CD47-SIRPα blocking agent and one or more anti-cancer agent(s), where the CD47-SIRPα blocking agents are represented by a compound of formula (I). The present invention also relates to a method of treating a cancer in a subject by administering a therapeutically effective amount of a CD47-SIRPα blocking agent represented by formula (I) in combination with one or more anti-cancer agent(s).

Combination of small molecule CD-47 inhibitors with other anti-cancer agents

The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.

Dual inhibitors of TIM-3 and PD-1 pathways

The present disclosure relates to methods comprising administering compounds that inhibit VISTA and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways with a compound that inhibits TIM-3 and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA, TIM-3, PD-1, PD-L1, and/or PD-L2.

Conjoint therapies for immunomodulation

The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, Ris the side chain of Ser, Ris —CO-Thr, Ris the side chain of Asn or Glu, and R, Rand Rare each H.

1,2,4-oxadiazole derivatives as immunomodulators

The present invention relates to method of modulating TIGIT signaling pathway and PD-1 signaling pathway. The invention also encompasses the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the treatment of diseases or disorders mediated by both TIGIT signaling pathway and PD-1 signaling pathway.

Method of modulating TIGIT and PD-1 signalling pathways using 1,2,4-oxadiazole compounds

The present invention provides a method of treating a disease or disorder with at least one SMARCA2/4 degrader, in a subject who are responders to such treatment based on the presence of tumor specific alterations described therein. The present invention also provides the methods for treating prostate cancer in the subjects who are likely to respond to treatment with SMARCA2/4 degraders.

Method for treating diseases using SMARCA2/4 degraders

The present invention relates to substituted alkynylene compounds represented by the compounds of formula (I), pharmaceutically acceptable salts and stereoisomers thereof. The present invention further provides the therapeutic uses of the compounds of formula (I) as anti-cancer agents.

Substituted alkynylene compounds as anticancer agents

The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.

1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways

The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I)  In the formula Q is O, Ris the side chain of Ser, Ris &#x2014;CO-Thr, Ris the side chain of Asn or Glu, and R, Rand Rare each H.

The present invention relates to 1,2,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

1,2,4-oxadiazole and thiadiazole compounds as immunomodulators

The present invention relates to a composition of a CD47-SIRP&#x3b1; blocking agent and one or more anti-cancer agent(s), where the CD47-SIRP&#x3b1; blocking agents are represented by a compound of formula (I). The present invention also relates to a method of treating a cancer in a subject by administering a therapeutically effective amount of a CD47-SIRP&#x3b1; blocking agent represented by formula (I) in combination with one or more anti-cancer agent(s).

1,2,4-oxadiazole compounds as inhibitors of CD47 signalling

The present invention relates to methods of modulating an immune response mediated by a PD-1 signaling pathway and of treating a cancer or an infectious disease. A subject is administered a compound(s) or a pharmaceutically acceptable salt or pharmaceutically acceptable composition thereof of formula (I)  In the ring Q is S or O. Rsubstituents are an optionally substituted side chain of the amino acid Ser or Thr and Rsubstituents are a side chain of the amino acids Asn, Asp, Gln, or Glu. Ris hydrogen or &#x2014;CO-Aaa and Aaa is Thr or Ser with a free, amidated or esterified C-terminus. Rand Rare independently hydrogen or absent. Ris hydrogen, alkyl or acyl.

Growing community of inventors

Bengaluru, India

Muralidhara Ramachandra